CARDIOLITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CARDIOLITE (CARDIOLITE).
Technetium Tc-99m sestamibi is a lipophilic cation that accumulates in myocardial cells via passive diffusion across the sarcolemmal and mitochondrial membranes. Its uptake is proportional to myocardial blood flow and viability, allowing for imaging of myocardial perfusion.
| Metabolism | Technetium Tc-99m sestamibi is not metabolized; it is cleared from the body primarily via the hepatobiliary system and eliminated in feces. Renal excretion accounts for a minor fraction. |
| Excretion | Renal: 85-90% as unchanged drug; fecal: <5% |
| Half-life | Terminal elimination half-life: 6-8 hours; prolonged in elderly and renal impairment (up to 12-16 hours). |
| Protein binding | ~98% bound to plasma proteins (primarily albumin and beta-globulins). |
| Volume of Distribution | Vd: 0.5-0.7 L/kg; indicates extensive distribution into tissues, particularly myocardium. |
| Bioavailability | IV: 100%; oral: not administered (degraded in GI tract). |
| Onset of Action | IV: within 1-2 minutes; oral: not applicable (radiopharmaceutical only given IV). |
| Duration of Action | Duration of imaging: 30-60 minutes; clinical effect (stress imaging): persists for duration of exercise or pharmacological stress. |
CARDIOLITE (Technetium-99m sestamibi) is administered intravenously. For myocardial perfusion imaging, adult dose: 10-40 mCi (370-1480 MBq), administered as a single bolus.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for impaired renal function; excretion is primarily biliary and fecal. |
| Liver impairment | No established Child-Pugh based dose modifications. Use with caution in severe hepatic impairment due to altered clearance. |
| Pediatric use | Weight-based dosing: 0.2-0.4 mCi/kg (7.4-14.8 MBq/kg) IV, minimum dose 2 mCi (74 MBq). |
| Geriatric use | No specific dose adjustment; standard adult dose used. Consider reduced renal function and comorbidities per clinical judgment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CARDIOLITE (CARDIOLITE).
| Breastfeeding | Technetium-99m pertechnetate is excreted into breast milk, but sestamibi is not excreted in significant amounts. However, due to the nature of the radiopharmaceutical, tracer amounts of technetium may be present. The M/P ratio is not established. Breastfeeding should be interrupted for at least 6-12 hours after administration to minimize infant exposure. Alternatively, pumping and discarding for 12 hours is recommended. |
| Teratogenic Risk | CARDIOLITE (technetium-99m sestamibi) is a diagnostic radiopharmaceutical. The radiation dose to the fetus from typical 25-40 mCi administration is approximately 0.5-1.5 mGy, which is below the threshold for deterministic effects (100 mGy). However, any radiation exposure carries a stochastic risk. There are no adequate studies in pregnant women. Use only if clearly needed, weighing potential benefit against risk. First trimester: highest risk for radiation-induced malformations; should be avoided if possible. Second and third trimesters: risk of later effects, particularly neurodevelopmental; may be used if diagnostic information is essential. |
■ FDA Black Box Warning
None listed in FDA labeling.
| Serious Effects |
["Known hypersensitivity to technetium Tc-99m sestamibi or any component of the formulation"]
| Precautions | ["Risk of radiation exposure; justify procedure by considering potential benefit.","Caution in patients with heparin use (may interfere with labeling of red blood cells if used for other studies).","Ensure adequate hydration to reduce radiation dose to bladder.","May cause transient hypotension, headache, or nausea."] |
| Food/Dietary | Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) for at least 24 hours before a pharmacologic stress test, as caffeine may interfere with the action of vasodilator stress agents (e.g., adenosine, regadenoson). No other specific food interactions. Maintain adequate hydration. |
Loading safety data…
| Fetal Monitoring | No specific monitoring beyond standard radiopharmaceutical protocols. In pregnant patients, ensure accurate gestational age and consider alternative imaging. Fetal monitoring is not routinely required. Monitor maternal vital signs during and after administration; report any signs of hypersensitivity. Document radiation exposure in patient record. |
| Fertility Effects | No known adverse effects on fertility based on available data. No studies have been conducted on CARDIOLITE's impact on human fertility. The estimated radiation dose to ovaries (0.2-0.5 mGy) is well below thresholds for infertility. |
| Clinical Pearls | Administer CARDIOLITE (technetium Tc-99m sestamibi) intravenously at rest and during stress (exercise or pharmacologic) for myocardial perfusion imaging. Ensure adequate hydration before and after injection to promote renal clearance. Interfering drugs: avoid theophylline and dipyridamole before pharmacologic stress; hold beta-blockers and calcium channel blockers for exercise stress if possible. Image acquisition typically 30-60 minutes post-injection. Use with caution in pregnancy and lactation; confirm negative pregnancy test if indicated. |
| Patient Advice | This is a radioactive tracer used to evaluate blood flow to your heart muscle. · You will receive an injection at rest and again during stress (exercise or medication). · Drink plenty of water before and after the procedure to help clear the tracer from your body. · Avoid caffeine (coffee, tea, soda, chocolate) for 24 hours before the stress test if pharmacological stress is planned. · Inform your doctor of all medications, especially asthma drugs (theophylline) and heart medications. · If you are pregnant, think you might be pregnant, or breastfeeding, tell your doctor before the test. · After the injection, you may need to wait 30-60 minutes before imaging begins. · Minimize close contact with pregnant women and infants for 24 hours after the procedure (e.g., maintain distance, avoid prolonged cuddling, sleep in separate bed). · The radiation exposure is similar to that from common diagnostic X-rays and is considered low risk. |